Goserelin
- Generic Name
- Goserelin
- Brand Names
- Zoladex
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N18O14
- CAS Number
- 65807-02-5
- Unique Ingredient Identifier
- 0F65R8P09N
- Background
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return...
- Indication
Goserelin is indicated for:
- Associated Conditions
- Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate
- Associated Therapies
- Palliative Treatment
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Atossa Therapeutics, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT05607004
- Locations
- 🇺🇸
Henry Ford Cancer Institute, Detroit, Michigan, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
- Conditions
- Interventions
- Drug: PIK3CA inhibitorDrug: AKT inhibitorDrug: SHR-A1811Drug: CarrelizumabDrug: SHR-1167Drug: FamitinibDrug: SorafenibDrug: EverolimusDrug: FluzoparibDrug: Aromatase Inhibitors or FulvestrantDrug: TPCDrug: SHR-A1921Drug: SHR-6209Drug: DalpiciclibDrug: ApatinibDrug: SHR-A2009Drug: SHR-A2102Drug: GoserelinDrug: bevacizumab
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 620
- Registration Number
- NCT05594095
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 716
- Registration Number
- NCT05582499
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China
Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- University Hospital, Akershus
- Target Recruit Count
- 85
- Registration Number
- NCT05163106
- Locations
- 🇳🇴
Akershus University Hospital, Lørenskog, Viken, Norway
Roll-over Study to Allow Continued Access to Ribociclib
- Conditions
- Interventions
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 137
- Registration Number
- NCT05161195
- Locations
- 🇺🇸
Poudre Valley Hospital, Fort Collins, Colorado, United States
🇺🇸Ironwood Cancer and Research Centers, Chandler, Arizona, United States
🇺🇸Highlands Oncology Group, Fayetteville, Arkansas, United States
Neoadjuvant Treatment of Breast Cancer
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- National Institute of Oncology, Hungary
- Target Recruit Count
- 300
- Registration Number
- NCT05131893
- Locations
- 🇭🇺
National Institute of Oncolgy, Budapest, Hungary
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 2050
- Registration Number
- NCT05050084
- Locations
- 🇺🇸
Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
🇺🇸Arizona Center for Cancer Care-Peoria, Peoria, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Phoenix, Phoenix, Arizona, United States
Goserline Acetate VS Dienogest in Endometriosi
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 40
- Registration Number
- NCT05013242
- Locations
- 🇪🇬
Mansoura University, Mansoura, الدقهلية, Egypt
Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant
- Conditions
- Interventions
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2
- Registration Number
- NCT04862143
- Locations
- 🇸🇪
Novartis Investigative Site, Orebro, Sweden
Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate
- Conditions
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT04736108
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.